JTR-161 / JCR Pharma, Teijin - LARVOL DELTA

A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) (clinicaltrials.gov) - P1/2 | N=79 | Completed | Sponsor: Teijin Pharma Limited | Active, not recruiting ➔ Completed | Trial completion date: May 2022 ➔ Nov 2021

Trial completion • Trial completion date • Cardiovascular • Ischemic stroke • CRP

Randomised placebo-controlled multicentre trial to evaluate the efficacy and safety of JTR-161, allogeneic human dental pulp stem cells, in patients with Acute Ischaemic stRoke (J-REPAIR). (PubMed, BMJ Open) - P1/2 | "NCT04608838; JapicCTI-194570 and Clinical Trials. gov."

Journal • Cardiovascular • Ischemic stroke

A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) (clinicaltrials.gov) - P1/2; N=79; Active, not recruiting; Sponsor: Teijin Pharma Limited; Trial completion date: Jul 2021 ➔ May 2022

Clinical • Trial completion date • Cardiovascular • Ischemic stroke • CRP • MRI

A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) (clinicaltrials.gov) - P1/2; N=79; Active, not recruiting; Sponsor: Teijin Pharma Limited; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Cardiovascular • Ischemic stroke • CRP • MRI

A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogenic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) (clinicaltrials.gov) - P1/2; N=76; Recruiting; Sponsor: Teijin Pharma Limited

Clinical • New P1/2 trial • Cardiovascular • Ischemic stroke